Humacyte, Inc. (HUMA) Stock Price & Analysis
Humacyte, Inc. (HUMA) fell 3.64% to USD 1.34 as of June 10, 2026 at 15:29 UTC, according to Nexqual real-time market data.
HUMA last closed at USD 1.39; the session ranged USD 1.31–1.49 on volume of 3,073,872 shares. Market capitalization is $297.39M, with a 52-week range of USD 0.55–2.84 (NMS). Source: Nexqual, June 10, 2026 at 15:29 UTC.
Key Statistics (as of June 10, 2026 at 15:29 UTC)
| Price | USD 1.34 |
|---|---|
| Change | ▼ 3.64% (down) |
| Previous Close | USD 1.39 |
| Open | USD 1.39 |
| Day Range | USD 1.31 – 1.49 |
| 52-Week Range | USD 0.55 – 2.84 |
| Volume | 3,073,872 shares |
| Market Cap | $297.39M |
| Exchange | NMS |
Technical Analysis (HUMA)
Nexqual's technical model rates HUMA "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of June 10, 2026 at 15:29 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 62.1 (neutral) |
| vs SMA50 | Above (USD 0.94) |
| MACD | 0.13 (positive) |
Analyst Ratings (HUMA)
Wall Street analysts rate HUMA "Buy" based on 5 analysts, with a mean price target of USD 1.9 (range USD 1–3), per Nexqual as of June 10, 2026 at 15:29 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 1.9 |
| High Target | USD 3 |
| Low Target | USD 1 |
| Buy / Hold / Sell | 4 / 1 / 0 |
Earnings (HUMA)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -0.12 |
| Revenue Estimate | $1.11M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.09 vs est -0.12 ▲ beat |
| 2025-12-31 | USD -0.13 vs est -0.14 ▲ beat |
| 2025-09-30 | USD -0.11 vs est -0.15 ▲ beat |
| 2025-06-30 | USD -0.24 vs est -0.18 ▼ miss |
Source: Nexqual, June 10, 2026 at 15:29 UTC.
Financials & Fundamentals (HUMA)
| Total Revenue | $2.02M |
|---|---|
| Revenue Growth (YoY) | -4.30% |
| Gross Margin | +0.00% |
| Operating Margin | -5704.04% |
| Profit Margin | +0.00% |
| ROE | -409.47% |
| Debt / Equity | 572.1 |
| Current Ratio | 3.93 |
| Total Cash | $48.54M |
| Total Debt | $66.50M |
| Free Cash Flow | $-64.81M |
Source: Nexqual, June 10, 2026 at 15:29 UTC.
Financial Health Score (HUMA)
Nexqual rates Humacyte, Inc.'s overall financial health "Critical" across five dimensions, as of June 10, 2026 at 15:29 UTC.
| Growth | Weak — Revenue -4% YoY (latest Q), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $49M cash vs $67M debt |
| Cash Flow | Weak — FCF negative: -$65M, burning cash |
| Efficiency | Critical — ROE -409%, ROA -51.5% |
Ownership (HUMA)
| Insider Ownership | +9.12% |
|---|---|
| Institutional Ownership | +26.92% |
| Shares Outstanding | 222.02M |
| Float | 190.57M |
| Short % of Float | +18.21% |
Source: Nexqual, June 10, 2026 at 15:29 UTC.
Leadership (HUMA)
Humacyte, Inc. is led by Laura E. Niklason (age 62), Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 15:29 UTC.
| Founder, President, CEO & Director | Laura E. Niklason (age 62) |
|---|---|
| CFO, Chief Corporate Development Officer & Treasurer | Dale A. Sander (age 65) |
| Executive Vice President of Enterprise Planning & Analysis | Lisa Molyneux |
| Executive Vice President Regulatory Affairs & Quality | Heather Connelly |
| Senior Vice President of Business Development | Rick McElheny |
Major Backers & Investors (HUMA)
Notable institutional backers of Humacyte, Inc. include Antipodes Partners Ltd., Great Point Partners LLC, UBS Group AG, according to Nexqual as of June 10, 2026 at 15:29 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Antipodes Partners Ltd. | 2.58% |
| Great Point Partners LLC | 1.69% |
| UBS Group AG | 1.25% |
| Fidelity | 1.13% |
| Woodline Partners LP | 0.9% |
| AQR Capital Management, LLC | 0.87% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.36% |
| Vanguard Group | 7.58% |
| Geode Capital | 1.65% |
| State Street | 1.37% |
Source: Nexqual, June 10, 2026 at 15:29 UTC.
From Humacyte, Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
- The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
- It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ABSI | Absci Corporation | USD 6.87 | ▲ 4.87% |
| SANA | Sana Biotechnology, Inc. | USD 2.83 | ▲ 5.2% |
| QSI | Quantum-Si Incorporated | USD 0.97 | ▼ 8.22% |
| ANNX | Annexon, Inc. | USD 4.96 | ▼ 3.22% |
| CRBU | Caribou Biosciences, Inc. | USD 1.79 | ▼ 2.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 15:29 UTC. This page is informational and not investment advice.